Understanding FDA De Novo Regulatory Clearance for Digital…

What is FDA De Novo Regulatory Clearance?

FDA De Novo clearance is a regulatory pathway designed to bring novel low-to-moderate risk medical devices, including digital therapeutics (DTx), to market. This process allows for the evaluation of new technologies that do not have substantial equivalent products already on the market.

The goal of De Novo clearance is to ensure that these innovative DTx products meet safety and effectiveness standards without requiring extensive premarket approval processes.

Steps in Obtaining FDA De Novo Clearance

To obtain De Novo clearance, manufacturers must submit a 510(k) premarket notification to the FDA. This document includes detailed information about the product’s design, performance data, and clinical evidence of safety and effectiveness.

The FDA then evaluates this submission to determine if the new DTx is substantially equivalent to a predicate device (a legally marketed device that does not require 510(k) clearance or premarket approval).

live demo · related simulation● LIVE

Why Does De Novo Matter for Digital Therapeutics?

De Novo clearance is crucial because it provides a clear pathway for DTx companies to bring their innovative products to market. This process ensures that these technologies meet regulatory standards while allowing them to compete in the healthcare marketplace.

Moreover, successful De Novo clearance can lead to increased investment and adoption of digital therapeutics by payers and patients.

Real-World Impact of FDA De Novo Clearance

Obtaining De Novo clearance for a DTx product can significantly impact patient outcomes. It allows healthcare providers to offer advanced, evidence-based digital interventions that can improve treatment adherence and overall health.

Additionally, it fosters innovation in the digital health sector by encouraging companies to develop new technologies that address unmet medical needs.

Frequently asked questions

What is a predicate device in the context of De Novo clearance?

A predicate device is a legally marketed device that does not require 510(k) clearance or premarket approval. In the De Novo process, it serves as the basis for comparison to determine if a new DTx product is substantially equivalent.

How long does the FDA De Novo process typically take?

The duration of the FDA De Novo process can vary significantly depending on the complexity of the submission and the thoroughness of the data provided. It generally takes several months to a year or more.

Can any digital health technology obtain De Novo clearance?

Not all DTx products are eligible for De Novo clearance. The FDA has specific criteria that must be met, such as the product being novel and low-to-moderate risk. Products that do not meet these criteria may require a more rigorous premarket approval process.

What happens if a DTx does not receive De Novo clearance?

If a DTx does not receive De Novo clearance, the company must either modify its product to fit within an existing regulatory category or pursue other regulatory pathways such as premarket approval (PMA) or de novo classification through a 510(k) submission.

Try it live

Everything above runs in your browser — open DTx Regulatory Clearance (FDA De Novo) Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open DTx Regulatory Clearance (FDA De Novo) Simulator simulation

Understanding FDA De Novo Regulatory Clearance for Digital Therapeutics